News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alchemia Release: Key Fondaparinux Patent Allowed by U.S. Patent Office


10/21/2008 10:58:42 AM

BRISBANE, Australia--(BUSINESS WIRE)--Australian drug developer Alchemia Limited (ASX:ACL) today announced it had received a ‘notice of allowance’ for the United States patent application titled Synthetic Heparin Pentasaccharides (number 10/488,677). A notice of allowance is a notification to the patent applicant that they are entitled to a patent under the law and is issued for applications that have been filed based on "intent to use." The patent number will be assigned on payment of the grant fees.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES